GeneralLast reviewed May 2026

FDA Form 483(Form 483)

A list of inspectional observations issued by FDA investigators at the end of a facility inspection when conditions may violate the FDCA or related acts.

Usage Examples

The pre-approval inspection closed with three Form 483 observations on data integrity.
The facility submitted its 15-day response detailing CAPAs for each observation.
Due diligence on the CDMO partner included review of recent Form 483 history.

What is Form 483?

FDA Form 483, formally Inspectional Observations, is the document an FDA investigator issues to facility management at the close of an inspection when objectionable conditions are observed. Each numbered observation describes a specific finding — typically a GMP, GCP, or GLP deviation — with reference to the regulation or expected practice. Form 483 observations are not a final FDA determination; they are the investigator's view of conditions at the time of inspection.

Facilities typically respond in writing within 15 business days of inspection close, explaining how each observation will be corrected. FDA reviews the response along with the establishment inspection report (EIR) and determines whether additional action is warranted — which can escalate to Warning Letters, Import Alerts, consent decrees, or enforcement actions depending on severity and correction adequacy.

Form 483 observations become public information after inspection close, typically searchable through FDA's FOIA process. Sponsors evaluating CMOs, CDMOs, CROs, and suppliers routinely review historical Form 483 records as part of due diligence. Recurring or uncorrected observations in subsequent inspections are a significant red flag for FDA and downstream customers.

Regulatory Context

This term appears most often in general workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDCA, 21 CFR 211, 21 CFR 820.

FDAICHHealth Canada

When This Matters

The pre-approval inspection closed with three Form 483 observations on data integrity.
The facility submitted its 15-day response detailing CAPAs for each observation.
Due diligence on the CDMO partner included review of recent Form 483 history.

Common Mistakes

Relying on generic terminology without mapping to the active jurisdiction context.
Skipping cross-links between terms, tools, and active regulatory references.
Failing to maintain a single source of truth for regulatory definitions internally.

Related Regulations

FDCA21 CFR 21121 CFR 820

Frequently Asked Questions

No. A Form 483 lists observations from a single inspection. A Warning Letter is a formal FDA enforcement action, typically issued when 483 observations are severe, recurring, or inadequately addressed. Most 483s do not escalate to Warning Letters; some do.

FDA expects a response within 15 business days to receive "most favorable consideration" by FDA when evaluating next steps. Responses after 15 days are still accepted but carry less weight. Responses should explain the root cause, immediate corrections, and long-term CAPA for each observation.

Yes, typically after the inspection closes. FDA publishes redacted Form 483s through FOIA responses. Sponsors, partners, and competitors can review historical 483 records when evaluating a facility. Recent 483s are searchable through the FDA Dashboard.